October 17, 2026 01:46 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
'How dare Elon Musk?' Owaisi defends Modi after billionaire's 'real boss' jibe at Ambani | 'B****y S***': IAS officer's abuse of female colleague during virtual J&K meeting sparks row | Aamir Khan’s nephew Imran Khan asked to leave India by Oct 28 after joining anti-CEC protest | ‘Their crime? Demanding justice’: Rahul Gandhi slams 4 AM detention of Ankita Bhandari’s parents | ‘Bangladesh showed us the way’: Neha Bora’s remarks spark BJP attack on Rahul Gandhi | Chingrighata flyover skid scare: Bikes fall, anti-skid blocks installed overnight as Bengal Minister Agnimitra Paul faces criticism | Meerut blue drum murder case: Muskaan, her lover get death sentence | 'Rise up, young patriots!': American singer Mary Millben alleges CJP gets US funding, urges peaceful protests | 'Won't go unchallenged': Muhammad Yunus heckling in New York triggers legal action warning | flydubai cockpit attack probe widens: Two Maldivian pilots detained in UAE over links to Omani co-pilot
Covid-19 Vaccine

Vaccine by itself will not end coronavirus pandemic: WHO Chief

| @indiablooms | Nov 17, 2020, at 04:20 am

Geneva/IBNS: World Health Organization (WHO) chief Tedros Adhanom Ghebreyesus on Monday said a vaccine would not by itself stop the coronavirus pandemic and cannot replace the other tools.

In a tweet, he said: A vaccine on its own will not end the COVID19 pandemic. We will still need to continue."

"Since the beginning of the COVID19 pandemic, we knew that a vaccine would be essential for bringing the pandemic under control. But it’s important to emphasise that a vaccine will complement the other tools we have, not replace them."

The remarks come on a day when American biotechnology company Moderna, Inc, said that its vaccine candidate against COVID-19 has shown 94.5 per cent efficiency.

The WHO chief mentioned that: "Initial supply of COVID19 vaccines will be limited, so healthworkers, older people & other at-risk populations will be prioritised. That will hopefully reduce the number of deaths & enable health systems to cope, but the virus will still have a lot room to move."

Moderna's study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID).

This first interim analysis was based on 95 cases, of which 90 cases of COVID-19 were observed in the placebo group versus 5 cases observed in the mRNA-1273 group, resulting in a point estimate of vaccine efficacy of 94.5% (p <0.0001).

Welcoming the progress, Stéphane Bancel, Chief Executive Officer of Moderna, said: “This is a pivotal moment in the development of our COVID-19 vaccine candidate. Since early January, we have chased this virus with the intent to protect as many people around the world as possible. This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease."

Bancel said, “This milestone is only possible because of the hard work and sacrifices of so many."
 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.